Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Le Lézard8d
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") . Such investors are advised to contact Danielle Peyton at ...
Pacbiztimes.com12d
Atara will shed 50% of its workforce after FDA rejection
Atara Biotherapeutics will be completing its third large-scale layoff in four years after the biotech company announced plans to shed 50% of its workforce by the end of June. Atara, a Thousand ...
HC Wainwright Issues Optimistic Outlook for ATRA Earnings
Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Atara ...
HC Wainwright Has Optimistic Outlook of ATRA Q3 Earnings
HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, January 28th. HC Wainwright analyst R. Burns now anticipates that the ...
Nasdaq14d
Where Will Iovance Biotherapeutics Be in 5 Years?
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...